Praziquantel
Mostrando 13-24 de 147 artigos, teses e dissertações.
-
13. Clinical-epidemiological and laboratory profiles of severe Schistosomiasis mansoni infections at a university hospital
OBJECTIVE: Schistosomiasis remains a public health problem. This was a descriptive and retrospective study of 42 patients with a severe form of schistosomiasis who were admitted to the outpatient clinic of the Faculdade de Medicina da Universidade de São Paulo, São Paulo, in São Paulo, Brazil. METHODS: A data collection questionnaire was designed from t
Clinics. Publicado em: 21/09/2018
-
14. Development of a Dissolution Test for Fenbendazole-Praziquantel Capsules Using UV-PLS Method
A dissolution test for capsules containing 50 mg of praziquantel and 500 mg of fenbendazole was developed and validated. The optimal conditions were an USP apparatus 2 with paddles rotating at 75 rpm, 900 mL dissolution medium (a mixture of 300 mL of ethanol and 600 mL 0.5 mol L-1 HCl), at 37.0 ± 0.5 °C. Both analytes achieved with sink conditions. A publi
J. Braz. Chem. Soc.. Publicado em: 2017-06
-
15. Synthesis and biological evaluation of novel imidazolidine derivatives as candidates to schistosomicidal agents
ABSTRACT Introduction: Schistosomiasis is an infectious parasitic disease caused by trematodes of the genus Schistosoma, which threatens at least 258 million people worldwide and its control is dependent on a single drug, praziquantel. The aim of this study was to evaluate the anti-Schistosoma mansoni activity in vitro of novel imidazolidine derivatives.
Rev. Inst. Med. trop. S. Paulo. Publicado em: 03/04/2017
-
16. Ultrastructural alterations in Schistosoma mansoni juvenile and adult male worms after in vitro incubation with primaquine
BACKGROUND Praziquantel has been cited as the only drug for treating schistosomiasis. However, concerns over drug resistance have encouraged the search for novel drug leads. The antimalarial drug primaquine possesses interesting anti-schistosmal properties. OBJECTIVES This study is the first to document the potential role of primaquine as a schistosomici
Mem. Inst. Oswaldo Cruz. Publicado em: 02/03/2017
-
17. Ultrastructural study of morphological changes in Schistosoma mansoni after in vitro exposure to the monoterpene rotundifolone
ABSTRACT INTRODUCTION: Schistosomiasis, a parasitic disease caused by trematode flatworms of the genus Schistosoma, affects more than 200 million people worldwide, and its control is dependent on a single drug, praziquantel. Here, we report the in vitro effect of rotundifolone, a monoterpene isolated from Mentha x villosa (Lamiaceae), on Schistosoma manson
Rev. Soc. Bras. Med. Trop.. Publicado em: 2017-02
-
18. Effects of (-)-6,6'-dinitrohinokinin on adult worms of Schistosoma mansoni: a proteomic analyses
Abstract Schistosomiasis, a chronic disease that affects million people worldwide, is caused by trematode flukes of the genus Schistosoma. The lack of an anti-schistosomiasis vaccine and massive monotherapy with praziquantel reinforces the need for search and development of new therapeutic drugs. Recently, we demonstrated that the essential oil of Piper cube
Rev. bras. farmacogn.. Publicado em: 2016-06
-
19. THE SUSCEPTIBILITY OF RECENT ISOLATES OF Schistosoma mansoni TO PRAZIQUANTEL
Introduction: Schistosomiasis is a chronic disease caused by trematode flatworms of the genus Schistosoma and its control is dependent on a single drug, praziquantel (PZQ), but concerns over PZQ resistance have renewed interest in evaluating the in vitro susceptibility of recent isolates of Schistosoma mansoni to PZQ in comparison with well-established str
Rev. Inst. Med. trop. S. Paulo. Publicado em: 23/02/2016
-
20. Antischistosomal activity from Brazilian marine algae
Abstract Schistosomiasis may be caused by six different species of the genus Schistosoma. Current treatment is based only on two drugs: oxamniquine, which is only effective against the Schistosoma mansoni species, and praziquantel, which is ineffective against young parasites. Therefore, research on new drugs and their targets for the treatment of this disea
Rev. bras. farmacogn.. Publicado em: 2015-12
-
21. Comparison between Ultraviolet and Infrared Spectroscopies for the Simultaneous Multivariate Determination of Pyrantel and Praziquantel
Methods based on multivariate calibration and diffuse reflectance infrared Fourier transform (DRIFT) and ultraviolet (UV) spectroscopies were developed for the simultaneous determination of two veterinary pharmaceutical drugs, pyrantel pamoate and praziquantel, in commercial tablets. The best UV model was obtained with the full spectra, 200-400 nm, and pa
J. Braz. Chem. Soc.. Publicado em: 2015-07
-
22. Development and Validation of a Dissolution Test Method for Albendazole and Praziquantel in Their Combined Dosage Form
A dissolution test method and an analytical procedure by HPLC were developed and validated for the evaluation of the dissolution of tablets containing albendazole and praziquantel. Two different commercially tablets containing 500 mg of albendazole and 50 mg of praziquantel for veterinary use were selected for this study. A dissolution medium containing a mi
J. Braz. Chem. Soc.. Publicado em: 2015-04
-
23. Evaluation of parasitological and molecular techniques for the diagnosis and assessment of cure of schistosomiasis mansoni in a low transmission area
This study evaluated parasitological and molecular techniques for the diagnosis and assessment of cure of schistosomiasis mansoni. A population-based study was performed in 201 inhabitants from a low transmission locality named Pedra Preta, municipality of Montes Claros, state of Minas Gerais, Brazil. Four stool samples were analysed using two techniques, th
Mem. Inst. Oswaldo Cruz. Publicado em: 2015-04
-
24. Current status of Paragonimus and paragonimiasis in Ecuador
A review of national and international publications on paragonimiasis in Ecuador, epidemiological records from the Ministry of Public Health and unpublished research data was conducted to summarise the current status of the parasite/disease. The purpose of the review is to educate physicians, policy-makers and health providers on the status of the disease an
Mem. Inst. Oswaldo Cruz. Publicado em: 14/10/2014